Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016
March 09 2016 - 7:46PM
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a
biopharmaceutical company focused on developing therapeutics to
stimulate the body's immune system to fight cancer, today announced
that it will report financial results for the third quarter of
fiscal year 2016 ended January 31, 2016 on March 9, 2016 prior to
market open and will host a conference call and webcast at 8:30 AM
Pacific Time (11:30 AM Eastern Time). Peregrine's senior management
will discuss financial results for the third quarter and review the
recent progress of its clinical development programs.
To listen to the live webcast, or access the
archived webcast, please visit:
http://ir.peregrineinc.com/events.cfm.
To listen to the conference call, please dial
(877) 312-5443 or (253) 237-1126 and request the Peregrine
Pharmaceuticals call.
About Peregrine Pharmaceuticals,
Inc.
Peregrine Pharmaceuticals, Inc. is a
biopharmaceutical company developing therapeutics to stimulate the
body's immune system to fight cancer. The company is focused
on evaluating its lead immunotherapy candidate, bavituximab, in
combination with a range of novel immuno-oncology (I-O) agents for
the treatment of various cancers. One specific component of
this I-O combination strategy includes planned clinical trials of
bavituximab in combination with durvalumab, AstraZeneca’s
investigational anti-PD-L1 immune checkpoint inhibitor, in a range
of cancer types under a clinical collaboration.
In addition to its drug development programs,
Peregrine also has in-house cGMP manufacturing capabilities through
its wholly-owned subsidiary Avid Bioservices, Inc.
(www.avidbio.com), which provides development and biomanufacturing
services for both Peregrine and third-party customers. For more
information, please visit www.peregrineinc.com.
Contacts:
Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024